Zoetis (NYSE:ZTS) Sets New 1-Year Low Following Analyst Downgrade

Zoetis Inc. (NYSE:ZTS)’s stock price hit a new 52-week low during mid-day trading on Tuesday after Stifel Nicolaus lowered their price target on the stock from $140.00 to $130.00. Stifel Nicolaus currently has a hold rating on the stock. Zoetis traded as low as $117.13 and last traded at $118.0360, with a volume of 648565 shares. The stock had previously closed at $118.80.

Several other research firms also recently issued reports on ZTS. Morgan Stanley decreased their price objective on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research note on Monday, November 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Argus reiterated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. BTIG Research cut their price objective on Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. Finally, UBS Group reduced their price objective on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $178.89.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Nova Wealth Management Inc. acquired a new stake in Zoetis in the 1st quarter valued at about $25,000. 1248 Management LLC purchased a new position in shares of Zoetis during the first quarter valued at $27,000. Halbert Hargrove Global Advisors LLC raised its position in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the period. Saudi Central Bank purchased a new stake in Zoetis in the 1st quarter worth about $29,000. Finally, REAP Financial Group LLC boosted its position in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 0.4%

The company has a market cap of $52.13 billion, a PE ratio of 20.36, a PEG ratio of 2.31 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a 50 day simple moving average of $139.63 and a two-hundred day simple moving average of $150.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same period in the prior year, the firm earned $1.58 earnings per share. The firm’s revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio is 33.67%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.